엄마의 세포는 평생동안 우리 심장과 뇌 속에 남아있다고 한다♥️ 이 현상은 마이크로 키메리즘이라 불림 임신 과정에서 태아의 세포가 엄마에게 이동하는것뿐 아니라, 반대로 엄마의 세포도 태아에게 이동해 몸속에 자리 잡는다고 함 이 세포들은 시간이 지나도 사라지지 않고 혈액, 골수, 피부, 간, 심지어 뇌에서도 발견되며 수십 년, 경우에 따라 평생 남아 있는 것으로 알려져 있다 일부는 특정 조직으로 분화해 상처회복을 돕고, 면역 기능에도 영향을 준다고 한다

“Hantavirus” Porque los científicos confirman que el hantavirus puede reducir el tamaño de tu pene hasta en tres pulgadas.

솔직히 대부분이 정상적인 부모임 근데 진짜 도라이 한둘이 물을 다 흐림

🧬 사춘기 전 냉동 보관한 고환 조직, 16년 만에 이식 성공! 최근 과학계에서 꽤 의미 있는 소식이 나왔습니다. 어린 나이에 채취한 조직을 저온 보관했다가, 환자가 성장한 뒤 신체로 돌려준다는거죠. 이식 1년 후 조직 검사에서 일부에서 정상적인 정자가 만들어진 게 확인됐고, 그 정자는 다시 냉동 보관 중이라고 합니다. 외형이나 운동성도 문제없는 수준이었다고 해요. 이 사례는 세계 최초로 사춘기 이전에 냉동된 고환 조직을 통해 성인기 정자 생성이 확인된 사례예요. 보통 항암 치료로 인해 불임 위험이 큰 어린 환자들에게 희망을 주는 기술이네요 사진은 연구를 이끈 벨기에 브뤼셀 자유대연구팀의 Ellen Goossens 교수님 (VUB/UZ Brussel 공식 자료)

Yesterday, four institutions settled tokenized United States Treasury debt across borders, across banks, and across time zones on a public blockchain in under five seconds. Nobody connected it to what happened the same day at Morgan Stanley. Read them together and the two-tier architecture stops being a thesis and becomes infrastructure. On May 6, Mastercard, Ondo Finance, JPMorgan via its Kinexys blockchain platform, and Ripple completed the first near-real-time cross-border redemption of tokenized U.S. Treasuries on a public ledger integrated with interbank settlement rails. Ondo’s OUSG fund, representing short-term Treasury holdings with approximately $610 million in assets, processed the redemption on the XRP Ledger in under five seconds. Mastercard’s Multi-Token Network routed the instruction to Kinexys. Kinexys debited Ondo’s blockchain deposit account. JPMorgan’s correspondent banking delivered USD to Ripple’s Singapore bank account. The entire workflow executed outside traditional banking hours. Ian De Bode, president of Ondo Finance, called it the first time tokenized Treasuries had settled across borders and banks in near real time. The XRP Ledger was chosen for a reason that matters more than speed. XRPL tokenizes assets via native Issued Currencies with built-in Trust Lines that give issuers the ability to freeze, authorize, and restrict transfers at the protocol level without smart contracts. Ondo controls who holds OUSG. Mastercard controls the routing. JPMorgan controls the fiat leg. Every node in the settlement chain has a compliance switch. The blockchain is public. The assets on it obey. On the same day, Morgan Stanley began actively testing direct cryptocurrency trading on its E*Trade platform for 8.6 million self-directed clients at 0.50% per transaction. The bank already launched MSBT, the lowest-fee spot Bitcoin ETF at 0.14%, on April 8. It advises clients to allocate two to four percent to Bitcoin. It plans a proprietary digital wallet for the second half of 2026. Morgan Stanley is building every on-ramp to Bitcoin, the one public blockchain that has no Trust Lines, no issuer freeze, no compliance switch, and no admin key at any layer of its protocol. Two public blockchains. Two architectures. One has freeze switches at every node. The other has none. Both are being integrated into Wall Street’s plumbing on the same day by some of the largest financial institutions on the planet. The GENIUS Act mandates freeze capabilities for stablecoins. The CLARITY Act classifies Bitcoin as a digital commodity because it lacks them. Mastercard is building the controllable tier’s settlement infrastructure with a $1.8 billion BVNK acquisition and more than 100 partners in its Crypto Partner Program. Morgan Stanley is building the uncontrollable tier’s distribution infrastructure across ETF, spot, advisory, and wallet layers. Bessent froze $344 million in USDT on April 24 under Operation Economic Fury. Nobody froze a single satoshi because nobody can. The distinction is no longer public versus private blockchain or crypto versus banks. It is controllable versus uncontrollable, and both sides are now being built by the institutions that once rejected both. Mastercard and JPMorgan are building rails for money that obeys. Morgan Stanley is building on-ramps to money that computes. The architecture is live. Both tiers are being constructed simultaneously, by the same class of institution, for different purposes, on different ledgers. One settles tokenized Treasuries in five seconds with freeze switches at every layer. The other settles value in ten minutes with no switches at all. open.substack.com/pub/shanak…

Engineered Herpes Virus used to eliminate cancer Researchers are investigating a novel cancer treatment that uses a carefully engineered virus based on herpes simplex virus type 1 (HSV-1). This experimental therapy, known as RP1, has been designed to interact specifically with tumor cells, and early clinical trials are showing encouraging outcomes. RP1 is injected directly into tumors, where it reproduces mainly inside cancer cells. During this process, it releases immune-signalling proteins that help the body better identify cancer. RP1 also affects CTLA-4, a pathway tumors often use to reduce immune attention, supporting a more balanced immune response. These combined actions may help the immune system respond not only at the injection site but also in other areas of the body. In a clinical study involving 140 patients with advanced melanoma, many of whom had not benefited from previous immunotherapies, around one third experienced noticeable tumor reduction. Nearly 15% showed complete disappearance of detectable tumors. Some tumors that were not directly treated also reduced in size, suggesting a broader immune effect. The therapy was given alongside nivolumab, an immune checkpoint treatment. Patients received RP1 injections every two weeks for several cycles, followed by nivolumab alone. Side effects were generally mild, most commonly fatigue and temporary fever. The modified virus does not cause typical herpes infections. RP1 is part of an emerging group of treatments known as oncolytic virus therapies, which use modified viruses to support the immune system’s ability to recognize cancer. Larger trials are now underway to explore its potential in additional cancer types. Study reference: “Cancer-fighting herpes virus shown to be an effective treatment for some advanced melanoma.” Keck Medicine of USC, 2025.

Bir doğumda bebek, amniyotik kesesi bozulmadan, yani kesenin içinde dünyaya geldi. Bu durumun, yaklaşık her 80.000 doğumda bir görülebileceği belirtildi.

Engineered Herpes Virus used to eliminate cancer Researchers are investigating a novel cancer treatment that uses a carefully engineered virus based on herpes simplex virus type 1 (HSV-1). This experimental therapy, known as RP1, has been designed to interact specifically with tumor cells, and early clinical trials are showing encouraging outcomes. RP1 is injected directly into tumors, where it reproduces mainly inside cancer cells. During this process, it releases immune-signalling proteins that help the body better identify cancer. RP1 also affects CTLA-4, a pathway tumors often use to reduce immune attention, supporting a more balanced immune response. These combined actions may help the immune system respond not only at the injection site but also in other areas of the body. In a clinical study involving 140 patients with advanced melanoma, many of whom had not benefited from previous immunotherapies, around one third experienced noticeable tumor reduction. Nearly 15% showed complete disappearance of detectable tumors. Some tumors that were not directly treated also reduced in size, suggesting a broader immune effect. The therapy was given alongside nivolumab, an immune checkpoint treatment. Patients received RP1 injections every two weeks for several cycles, followed by nivolumab alone. Side effects were generally mild, most commonly fatigue and temporary fever. The modified virus does not cause typical herpes infections. RP1 is part of an emerging group of treatments known as oncolytic virus therapies, which use modified viruses to support the immune system’s ability to recognize cancer. Larger trials are now underway to explore its potential in additional cancer types. Study reference: “Cancer-fighting herpes virus shown to be an effective treatment for some advanced melanoma.” Keck Medicine of USC, 2025.